Scholars Academic Journal of Pharmacy
Abbreviated Key Title: Sch Acad J Pharm
ISSN 2347-9531 (Print) | ISSN 2320-4206 (Online)
Journal homepage: http://saspublishers.com

OPEN ACCESS

Pharmacy Practice

Tay – Sachs Disease

Gollapalli Eswari[1*], Simhavalli.Godavarthi[1], Sneha Kuraman[1], Malla.Jnaapika[1], V. C. Randeep Raj[2]

[1]Avanthi Institute of Pharmaceutical Sciences, Vizianagaram, Cherukupally, Andhra Pradesh, India
[2]Asst. Professor, Department of Pharmacy Practice, Avanthi Institute of Pharmaceutical Sciences, Vizianagaram, Andhra Pradesh, India

DOI: 10.36347/sajp.2021.v10i07.001 | **Received:** 19.04.2021 | **Accepted:** 02.06.2021 | **Published:** 04.07.2021

***Corresponding author:** Gollapalli Eswari

Abstract **Review Article**

Tay-Sachs disease is a rare hereditary disease that increasingly destroys nerve cells (neurons) in the brain and nerve structure. The foremost common variety of monogenic disorder becomes apparent in infancy. Babies with this disease usually look traditional till the age of three to six months, once their development slows and muscles used for movement weaken. Affected infants lose motor skills like turning over, sitting, and travel. They additionally develop Associate in nursing exaggerated start to loud noises. Because the sickness progresses, youngsters with monogenic disorder expertise seizures, vision and deafness, intellectual incapacity, and disfunction. Youngsters with this severe infantile variety of monogenic disorder sometimes live solely into infancy.

Keywords: Hereditary, neural structure, monogenetic, seizures, deafness.

INTRODUCTION

Tay-Sachs disease (TSD) is defined as a hereditary neurodegenerative disorder resulting from excess storage of GM2 ganglioside within the lysosomes of cells. Lysosomes contain a sort of active hydrolytic enzymes referred to as hydrolases, including glycosidases, phosphatases, sulphatases, lipases, proteases, phospholipases, and nucleases [1]. Deficiency of only one of these hydrolases result in the lack to degrade macromolecules and, as a consequence, a lysosomal storage disease. GM2 gangliosidoses are chromosomal recessive disorders caused by the deficiency of β-hexosaminidase, which successively cause excessive intralyosomal accumulation, significantly in neuronal cells [2]. There are two types of isoenzymes of β-hexosaminidase: hexosaminidase A (HexA), a heterodimer formed by two subunits (α and β), and hexosaminidase B (HexB), a homodimer also formed by two subunits (β- and β). There also are three sorts of GM2 gangliosidosis: Tay-Sachs disease (TSD), Sandhoff disease (SD) and GM2 activator deficiency [3]. TSD was first described in 1881, but its aetiology remained unknown for a long time, and affected new-borns could only be diagnosed after the first clinical manifestations [4]. TSD occurs most frequently in children with intellectual disability, skill regression, dementia, paralysis and blindness, and it, usually, results in death by age 5. The incidence of the disease is estimated to be 1 in 3600 in Ashkenazi Jews with carrier frequency of 1 in 300. Tay-Sachs disease is the most often occurring sphingolipidoses [5].

Epidemilogy

- Tay Sachs disease is rare in the general population and estimated prevalence is about 1 in 1, 00,000 live births, whereas the carrier frequency is about 1 in 250.
- Parental consanguinity is a main risk factor for this manifestation of this Autosomal recessive Genetic disease, which shows mutations in the HEXA gene at higher allele.
- The disease is more frequent in the people of Ashkenazi Jewish heritage i.e, those of central or Eastern European descent [6].
- These Epidemiological studies on carrier state in the Jewish community in the US showed a prevalence of about 1 in 29, and 1 in 3500 life birth is affected.
- Along with this community the canjun community of lousiana, an old order amish community in Pennsylvania, and also Non-Jewish French Canadians lining near St.Lawrence also have a high incidence of Tay Sachs Disease [7].

CLASSIFICATION

1. **Classic Infantile Tay-Sachs**

- Symptoms seem around six months older. Oldsters could notice a discount in vision and pursuit and also the baby doesn't outgrow traditional jump.
- Infantile autosomal recessive disease youngsters step by step regress, losing skills one by one. Over time they're unable to crawl, turn over, sit or reach out. Alternative symptoms embody loss of coordination, progressive inability to swallow and issue respiratory [8].
- By age two and on the far side, most youngsters expertise continual seizures and eventually lose muscle operate, mental operate and sight, changing into largely non-responsive to their setting [9].

2. Juvenile Tay-Sachs

- Symptoms usually seem between ages two and five, however will occur anytime throughout childhood.
- Early symptoms of Juvenile autosomal recessive disease embody lack of coordination or clumsiness and muscle weakness like scuffling with stairs. A toddler may additionally exhibit unintelligible speech, swallowing difficulties and muscle cramps [10].
- Over time, youngsters with Juvenile autosomal recessive disease slowly decline, losing their ability to steer, worry their own and communicate. Youngsters square measure liable to metabolic process infections and sometimes expertise continual bouts of respiratory disease. Several have seizures [11].
- Juvenile autosomal recessive disease features a broad vary of severity. In most cases, the sooner the primary signs square measure ascertained, the additional quickly the sickness can progress [12].

3. Late Onset Tay-Sachs

- Symptoms usually seem in adolescence or early adulthood, however will seem later.
- Early symptoms currently Onset autosomal recessive disease (LOTS) embody clumsiness and muscle weakness within the legs. Once diagnosed, adults typically mirror back to their childhood and will notice experiencing symptoms abundant earlier like not being athletic and/or speech difficulties or a stutter as a toddler or juvenile person [13].
- The psychological state symptoms could gift 1st which might result in AN particularly long road to designation. Concerning four-hundredth of affected adult's expertise psychological state symptoms like bi-polar or psychotic episodes [14].
- Gradual Loss of skills - Over time adults with Late Onset autosomal recessive disease slowly decline. Adults ofttimes need additional quality help, i.e. cane to walker to chair. Several expertise speeches and swallowing difficulties however few need a feeding tube [15].

PATHOPHYSIOLOGY

Tay - Sachs disease could be a progressive and fatal genetic condition that involves a whole deficiency of the hexosaminidase-A (HEXA) catalyst. This catalyst is required in healthy people for the method of reaction of GM2 ganglioside to occur for people with lipidosis that lack this catalyst; the fatty substance of GM2 ganglioside accumulates within the brain and results in the symptoms of the unwellness [16].

Role of Hexosaminidase

A hydrolytic HEXA catalyst sometimes plays a necessary role within the method to interrupt down glycolipids within the lysosomes. Aboard alternative enzymes, it's chargeable for the breakdown of specific carboxylic acid derivatives called gangliosides [17]. There are 3 proteins needed for the reaction of GM2-gangliosides: the alpha and beta subunits of hexosaminidase, and therefore the GM2 matter macromolecule needed as a chemical compound for the enzymes [18]. It's the absence of the alpha fractional monetary unit, called HEXA,that plays a very vital role within the pathophysiology of lipidosis. Result in Absence of Functioning Hexosaminidase A In the early stages of life because the brain develops, gangliosides are naturally made and biodegraded at a quick rate. Within the absence of the HEXA catalyst, the natural reaction reaction of the gangliosides cannot occur as traditional. This may cause an accumulation of the lipids within the brain, central system and therefore the membrane of the eyes [19].

DIAGNOSIS

1. Diagnosis and carrier testing

a. Indications for carrier testing
   - i. Fully or partially Jewish
   - ii. Pennsylvania Dutch
   - iii. Cajuns of Southern Louisiana
   - iv. French Canadians of Eastern Quebec

b. Preconceptional counseling for at-risk couples

c. Enzyme assay
   - i. Using fluorimetric study measuring activity of both Hex A and Hex B in either serum or leukocytes
   - ii. Decreased activity of Hex A with normal or increased activity of Hex B in carriers
   - iii. Limitations of serum assay

a. Overlapping of the values between carriers and noncarriers

b. Unreliable in pregnant women and in women taking oral contraceptives

c. Inability to distinguish carriers of pseudo deficiency alleles from carriers of disease causing mutations

iv. Clarification of abnormal or inconclusive results of enzyme assay by:

a. Enzyme assay on leukocytes

b. DNA mutation analysis for common mutations and pseudodeficiency alleles

2. CT scan of the brain: areas of low density in the basal ganglia and cerebral white matter
3. MRI of the brain: an increased signal in the basal ganglia and cerebral white matter on T2-weighted images
4. Characteristic neuropathological findings
   a. Pathologic changes are restricted to the nervous system
   b. Ballooning of neurons with massive intralysosomal accumulation of lipophilic membranous bodies
   c. Nature and structure of the stored intraneuronal material: GM2 ganglioside
   d. Abnormal cytoplasmic inclusion bodies identified in fetal spinal cord at 12 weeks and retina and spinal ganglia during 19th–22nd week of gestation
   e. Cisternae of the endoplasmic reticulum: the primary site of lipid accumulation in neurons during the fetal stage of Tay-Sachs disease [20].

General treatment

There is no approved effective treatment for TSD or a way to stop its progression Death usually occurs before age 5 and is often associated with aspiration pneumonia and bronchoaspiration [6]. Gene therapies to restore enzymes in patients could cure such diseases, but time, vector type and kinetics in enzyme production require extensive optimization. Intracerebroventricular administration of mod2B reduced the accumulation of GM2 in the cerebellum, hippocampus and hypothalamus and significant improvement in motor function will be observed. mod2B is a modified human hexosaminidase subunit β [21]. This is composed of homodimeric subunit β containing amino acid sequences from the subunit α that degraded GM2 gangliosides. Substrate reduction therapy and the production of GM2 gangliosides will not show any response in the prevention of neurodegeneration [22]. Respiratory care like chest physiotherapy can be used to reduce mucus to solve the difficulties with breathing. Nasogastric (NG) tubes help to deliver nutrients through the nose and oesophagus into the stomach. Physical therapy can be done to prevent deterioration of neurological and motor functions in TSD patients [23].

CONCLUSION

TSD is associate chromosome recessive neurodegenerative disorder caused by the deficiency of the lysosomal catalyst catalyst A (HexA) that end in the build-up of GM2 gangliosides chiefly in neurons. It's associate calculable prevalence of one per 220 000 people and patients sometimes die before five years archaic. There's no effective treatment approved neither to treat TSD nor to prevent its progression; but varied strategies are explored to revive the operate of β-hexosaminidase A. gene therapies to revive enzymes in patients might supply treatment for these diseases however; a lot of studies and analysis are required as they presently have multiple limitations. Gathering existing data on the pathology permits action the importance of conducting analysis on this malady so as to produce timely treatment and attains good prognosis for patients.

Author's contribution

All authors contributed equally to this work.

REFERENCES

1. Ferreira, C. R., & Gahl, W. A. (2017). Lysosomal storage diseases. *Translational science of rare diseases*, *2*(1-2), 1-71.
2. Cachón-González, M. B., Wang, S. Z., Ziegler, R., Cheng, S. H., & Cox, T. M. (2014). Reversibility of neuropathology in Tay–Sachs-related diseases. *Human molecular genetics*, *23*(3), 730-748.
3. Kato, A., Nakagome, I., Nakagawa, S., Kinami, K., Adachi, I., Jenkinson, S. F., ... & Hirono, S. (2017). In silico analyses of essential interactions of iminosugars with the Hex A active site and evaluation of their pharmacological chaperone effects for Tay–Sachs disease. *Organic & biomolecular chemistry*, *15*(44), 9297-9304.
4. Dersh, D., Iwamoto, Y., & Argon, Y. (2016). Tay–Sachs disease mutations in HEXA target the α chain of hexosaminidase A to endoplasmic reticulum–associated degradation. *Molecular biology of the cell*, *27*(24), 3813-3827.
5. Forster, C. S. (2014). 50 Years Ago in The Journal of Pediatrics: The Startle Response and Serum Enzyme Profile in Early Detection of Tay-Sachs' Disease. *The Journal of pediatrics*, *165*(5), 944.
6. Zigdon, H., Meshcheriakova, A., & Futerman, A. H. (2014). From sheep to mice to cells: tools for the study of the sphingolipidoses. *Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids*, *1841*(8), 1189-1199.
7. Song, W., Wang, F., Savini, M., Ake, A., Di Ronza, A., Sardiello, M., & Segatori, L. (2013). TFEB regulates lysosomal proteostasis. *Human molecular genetics*, *22*(10), 1994-2009.
8. Sharma, S., Sankhyan, N., Kalra, V., & Garg, A. (2008). Thalamic changes in Tay-Sachs' disease. *Archives of neurology*, *65*(12), 1669-1669.
9. Anheuser, S., Breiden, B., Schwarzmann, G., & Sandhoff, K. (2015). Membrane lipids regulate ganglioside GM2 catabolism and GM2 activator protein activity [S]. *Journal of lipid research*, *56*(9), 1747-1761.
10. Barone, R., Sturiale, L., Fiumara, A., Palmigiano, A., Bua, R. O., Rizzo, R., ... & Garozzo, D. (2016). CSF N- glycan profile reveals sialylation deficiency in a patient with GM2 gangliosidosis presenting as childhood disintegrative disorder. *Autism Research*, *9*(4), 423-428.

11. Deik, A., & Saunders- Pullman, R. (2014). Atypical presentation of late- onset Tay- sachs disease. *Muscle & nerve*, *49*(5), 768-771.
12. Nakamura, S., Saito, Y., Ishiyama, A., Sugai, K., Iso, T., Inagaki, M., & Sasaki, M. (2015). Correlation of augmented startle reflex with brainstem electrophysiological responses in Tay–Sachs disease. *Brain and Development*, *37*(1), 101-106.
13. Georgiou, T., Christopoulos, G., Anastasiadou, V., Hadjiloizou, S., Cregeen, D., Jackson, M., ... & Drousiotou, A. (2014). The first family with Tay-Sachs disease in Cyprus: Genetic analysis reveals a nonsense (c. 78G> A) and a silent (c. 1305C> T) mutation and allows preimplantation genetic diagnosis. *Meta Gene*, *2*, 200-205.
14. Karimzadeh, P., Jafari, N., Biglari, H. N., Dari, S. J., Abadi, F. A., Alaee, M. R., ... & Ghofrani, M. (2014). GM2-Gangliosidosis (Sandhoff and Tay Sachs disease): diagnosis and neuroimaging findings (an Iranian pediatric case series). *Iranian journal of child neurology*, *8*(3), 55.
15. Abalem, M. F., Francischini, S., Carricondo, P. C., & Graziano, R. M. (2014). Fundus autofluorescence in Tay-Sachs disease. *JAMA ophthalmology*, *132*(7), 876-876.
16. Wolfson, W. (2013). Solving for x: accelerators could speed search for rare disease therapies. *Chemistry & biology*, *20*(12), 1435-1437.
17. Hallam, S., Nelson, H., Greger, V., Perreault-Micale, C., Davie, J., Faulkner, N., ... & Kennedy, C. J. (2014). Validation for clinical use of, and initial clinical experience with, a novel approach to population-based carrier screening using high-throughput, next-generation DNA sequencing. *The Journal of Molecular Diagnostics*, *16*(2), 180-189.
18. Hussein, N., Weng, S. F., Kai, J., Kleijnen, J., & Qureshi, N. (2018). Preconception risk assessment for thalassaemia, sickle cell disease, cystic fibrosis and Tay- Sachs disease. *Cochrane Database of Systematic Reviews*, (3).
19. LJ, P. G., Gómez, J. F., Botero, V., & Pachajoa, H. (2016). Clinical, biochemical, and molecular findings in a Colombian patient with Tay-Sachs disease. *Neurologia (Barcelona, Spain)*, *33*(1), 61-63.
20. Bley, A. E., Giannikopoulos, O. A., Hayden, D., Kubilus, K., Tifft, C. J., & Eichler, F. S. (2011). Natural history of infantile GM2 gangliosidosis. *Pediatrics*, *128*(5), e1233-e1241.
21. Krishnamoorthy, K. S., Eichler, F., Rapalino, O., & Frosch, M. P. (2014). Case 14-2014: An 11-Month-Old Girl with Developmental Delay. *New England Journal of Medicine*, *370*(19), 1830-1841.
22. Zeesman, S., McCready, E., Sadikovic, B., & Nowaczyk, M. J. (2015). Prader–Willi syndrome and Tay–Sachs disease in association with mixed maternal uniparental isodisomy and heterodisomy 15 in a girl who also had isochromosome Xq. *American Journal of Medical Genetics Part A*, *167*(1), 180-184.
23. Clayton, T. (2017). Ethical Issues with Genetic Testing for Tay-Sachs. *Journal of Christian Nursing*, *34*(4), 246-249.